Latest News

We are expanding our in vitro/ex vivo analysis capacity

At Redoxis, we have a fully equipped lab for work with both primary cells and cell lines. We also hava fully equipped laboratory for post experiment follow up analyses and stand alone immunology assays. We have during the fall further enhanced our capacity for such studies by acquiring an Attune NxT flow cytometer (Thermo Fisher […]

Read more

Pharmaoutsourcing in Stockholm 9th December

In the 9th of December we will attend the PHARMA OUTSOURCING meeting in Stockholm-  This is a new annual international partnering meeting for Investment Managers and R&D professionals in biotech-, pharma-, virtual- and start up companies to meet, network and discuss best practices in pharma outsourcing.

Read more

NEURINOX gathers top researchers, patients and industry in an international symposium on innovative concepts for treating neurodegenerative diseases

Neurodegeneration leads to chronic debilitating diseases, including age-related syndromes like Alzheimer’s and Parkinson’s diseases and disorders affecting younger people such as epilepsy and multiple sclerosis. A common disease mechanism in neurodegeneration is inflammation of the brain, also referred to as neuroinflammation. Neurinox, a 5-year international biomedical research project running until the end of 2016, was […]

Read more

Meeting partners and NLS days in Stockholm 9-10 september

Attending one of the largest partnering event in Life Science, these days taking place in Stockholm 9-10 September- 2015. This will be an event not only to meet with research partners and Sponsors for Redoxis preclinical models of autoimmunity, but also initiation of discussion with partners for next call to H2020.

Read more

Tax reduction eligibility for Redoxis services

Redoxis has been approved by the French authorities “Ministère chargé de l’Enseignement supérieur et de la Recherche” eligible for tax reduction for services performed by Redoxis for French research entities. For further information please contact us at service@redoxis.com or directly to Peter Olofsson, CEO or Malin Hutqvist, CSO.    

Read more